Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1027-1032. doi: 10.19723/j.issn.1671-167X.2018.06.015

• Article • Previous Articles     Next Articles

Increased serum soluble-endoglin level and its clinical significance in antiphospholipid syndrome

Ji LI1,2,Li ZHENG1,Lian-jie SHI2,Jing XU2,Jian-long SHU3,Xue-wu ZHANG3,△()   

  1. 1. Department of Rheumatology and Immunology, Peking University People’ s Hospital, Beijing 100044, China
    2. Department of Rheumatology and Immunology, Peking University International Hospital, Beijing 102206, China
    3. Department of Rheumatology and Immunology, Guangxi International Zhuang Medical Hospital, Nanning 530011, China
  • Received:2018-07-10 Online:2018-12-18 Published:2018-12-18
  • Contact: Xue-wu ZHANG E-mail:xuewulore@163.com

RICH HTML

 7   

PDF (PC)

308

Abstract:

Objective: To detect the serum levels of soluble endothelial glycoprotein endoglin (s-Eng) in patients with antiphospholipid syndrome(APS) and to evaluate the correlation between s-Eng levels and clinical features and laboratory parameters.Methods:The levels of serum s-Eng were measured by enzyme linked immunosorbent assay ( ELISA) in 139 patients with APS, 44 patients with SLE but no APS, 37 patients with primary Sjogren’s syndrome (pSS), 23 patients with Bechet’s disease (BD), 22 patients with systemic sclerosis (SSc) and 22 persistent anticardiolipin antibody (aCL) positive indivi-duals without SLE or APS(simply aCL positive group) and 87 health controls(HC) without any auto-immune diseases. These APS patients included 64 primary APS patients and 75 APS patients secondary to SLE.The correlation between the clinical data, laboratory parameters, and serum s-Eng levels were analyzed.Independent samples t test,paired t test,Chi-square Test, Mann-Whitney U test, Pearson’s χ 2 test were used for statistical analyses. Results:(1)The serum levels of s-Eng were significantly higher in the patients with APS whether primary or secondary to SLE than in the health controls and simply aCL positive group and the patients with other autoimmune diseases, including SLE, pSS, BD and SSc(P<0.001).There was no significant difference in the serum s-Eng levels between simply aCL positive group and health controls[(5.17±2.00) mg/L vs.(5.04±1.11) mg/L, P>0.05]. (2) The best cut-off value for the diagnosis of APS was no less than 8.37 mg/L as mean ± 3SD value, with the sensitivity at 0.772 and the specificity at 0.928. The Youden index was 0.700. These results indicated good validity of s-Eng as a diagnostic marker for APS. (3)The proportions of artery thrombosis and pathological pregnancy were higher in the group of s-Eng -positive APS patients than that in s-Eng -negative group(46/81 vs. 19/58,29/65 vs. 10/44,respectively, all P<0.05).The levels of PLT were lower in the group of s-Eng-positive APS patients (72.00×10 9/L vs. 119.00×10 9/L, P<0.001). (4)The proportions of the presence(93.83% vs. 37.93%, P<0.001) and titer (61.70 U/mL vs.15.45 U/mL, P<0.001) of aCL were both higher in the group of s-Eng-positive APS patients than in s-Eng-negative group. The proportions of the presence (61.73% vs. 43.10%, P<0.05)and titer (33.48 U/mL vs.17.40 U/mL,P<0.05) of anti-β2-glycoproteinⅠ antibody were both higher in the group of s-Eng -positive APS patients than in s-Eng -negative group too. Conclusion:S-Eng serum levels were significantly increased in the patients with APS, and it may play a role as acomplementary serological marker for the diagnosis and risk prediction of APS.

Key words: Soluble endoglin, Antiphospholipid syndrome, Thrombosis, Pathological pregnancy, Antiphospholipid antibody

CLC Number: 

  • R593.2

Table 1

Clinical manifestation and laboratorycharacteristics of APS patients"

Parameter APS patients (n=139)
Demographic data
Age/years, x-±s 43.05±15.33
Disease duration/years, x-±s 4.35±2.92
Male / female 30/109
Clinical manifestation
Tarombokinesis 137/139 (98.56%)
Arterial thrombosis 65/139 (46.76%)
Venous thrombosis 96/139 (58.27%)
Microvascular thrombosis 15/139 (10.79%)
Obstetrical complications 39/109 (35.78%)
Dead fetus in uterus 22/109 (20.18%)
Spontaneous abortion ≥3 times 14/109 (9.17%)
Preeclampsia 3/109 (2.75%)
Laboratory characteristics
Hematological disease 67/139 (48.25%)
Thrombocytopenia 85/139 (61.2%)
Anemia 39/139 (60.43%)
ANA 84/139 (60.43%)
LA 15/24 (62.5%)
aCL 98/139 (70.50%)
Antiβ2-GPⅠ 75/139 (53.96%)

Figure 1

Serum s-Eng levels of APS patients, other rheumatic disease patients, simply aCL positive group and the health control* P <0.01;▲ P<0.001;s-Eng, soluble endoglin;APS, antiphospholipid syndrome;SLE, systemic lupus erythematosus;pSS, primary Sjogren’s syndrome;BD, Behcet’s disease;SSc, systemic sclerosis;ACL(+), anticardiolipin antibody positive;HC, health control."

Figure 2

Serum levels of s-Eng between patients with pAPS and APS secondary to SLEs-Eng, soluble endoglin;pAPS, primary antiphosphlipid syndrome;APS, antiphosphlipid syndrome;SLE, systemic lupus erythematosus;NS, no statistics."

Figure 3

ROC curves of s-Eng for identification of APS"

Table 2

Comparison of clinical and laboratory features between patients with positive s-Eng and those with negative s-Eng"

Parameter s-Eng(+) s-Eng(-) P
Demographic data
Age/years, x-±s 43.05±15.32 41.10±15.00 0.491
Disease duration /years, x-±s 4.42±3.17 4.20±2.22 0.686
Male/female 16/65 14/44 0.535
Clinical feature
Tarombokinesis 80/81 57/58 1.000
Arterial thrombosis 46/81 19/58 0.005
Venous thrombosis 59/81 37/58 0.255
Microvascular thrombosis 11/81 4/58 0.210
Obstetrical complications 29/65 10/44 0.019
Dead fetus in uterus 15/65 7/44 0.360
Spontaneous abortion ≥3 times 12/65 2/44 0.033
Preeclampsia 2/65 1/44 0.799
Laboratory examination
Hematological disease 63/81 26/58 <0.001
WBC(×109/L), x-±s 6.11±3.45 5.87±3.87 0.720
PLT(×109/L), M(P25,P75) 72.00 (52.00, 99.70) 119.00 (89.75, 162.70) <0.001
HGB/(g/L), x-±s 120.63±28.89 128.23±26.09 0.147
LA (+) 18/81 11/58 0.928
aCL (+) 76/81 22/58 <0.001
Antiβ2-GPⅠ (+) 50/81 25/58 0.030
[1] Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006,4(2):295-306.
doi: 10.1111/jth.2006.4.issue-2
[2] Pierangeli SS, Colden-Stanfield M, Liu X , et al. Antiphospholi-pid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo[J]. Circulation, 1999,99(15):1997-2002.
doi: 10.1161/01.CIR.99.15.1997
[3] Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B , et al. NFκB is an essential intermediate in the activation of endothelial cells by anti-β2-glycoprotein 1 antibodies[J]. Thromb Haemost, 2002,88(5):851-857.
doi: 10.1055/s-0037-1613313
[4] Charakida M, Besler C, Batuca JR , et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome[J]. JAMA, 2009,302(11):1210-1217.
doi: 10.1001/jama.2009.1346
[5] Ames PR, Batuca JR, Ciampa A , et al. Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome[J]. J Rheumatol, 2010,37(12):2523-2530.
doi: 10.3899/jrheum.100494 pmid: 20889602
[6] Ramesh S, Morrell CN, Tarango C , et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2[J]. J Clin Invest, 2011,121(1):120-131.
doi: 10.1172/JCI39828 pmid: 3007129
[7] Toporsian M, Gros R, Kabir MG , et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia[J]. Circ Res, 2005,96(6):684-692.
doi: 10.1161/01.RES.0000159936.38601.22 pmid: 15718503
[8] Alt A, Miguel-Romero L, Donderis J , et al. Structural and functional insights into endoglin ligand recognition and binding[J]. PLoS One, 2012,7(2):e29948.
doi: 10.1371/journal.pone.0029948 pmid: 22347366
[9] Bernabeu C, Conley BA, Vary CP . Novel biochemical pathways of endoglin in vascular cell physiology[J]. J Cell Biochem, 2007,102(6):1375-1388.
doi: 10.1002/jcb.21594 pmid: 17975795
[10] Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA , et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients[J]. BMC Med, 2010,8:86.
doi: 10.1186/1741-7015-8-86 pmid: 21171985
[11] Strasky Z, Vecerova L, Rathouska J , et al. Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice[J]. Circ J, 2011,75(7):1747-1755.
doi: 10.1253/circj.CJ-10-1285 pmid: 21576826
[12] Vitverova B, Blazickova K, Najmanova I , et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta[J]. Atherosclerosis, 2018,271:15-25.
doi: 10.1016/j.atherosclerosis.2018.02.008 pmid: 29459262
[13] Emeksiz HC, Bideci A, Damar Ç , et al. Soluble endoglin level increase occurs prior to development of subclinical structural vascular alterations in diabetic adolescents[J]. J Clin Res Pediatr Endocrinol, 2016,8(3):313-320.
doi: 10.4274/jcrpe
[14] Rathouska J, Jezkova K, Nemeckova I , et al. Soluble endoglin, hypercholesterolemia and endothelial dysfunction[J]. Atherosclerosis, 2015,243(2):383-388.
doi: 10.1016/j.atherosclerosis.2015.10.003 pmid: 26520890
[15] Bassyouni IH, El-Shazly R, Azkalany GS , et al. Clinical significance of soluble-endoglin levels in systemic lupus erythematosus: possible association with anti-phospholipid syndrome[J]. Lupus, 2012,21(14):1565-1570.
doi: 10.1177/0961203312460115 pmid: 22941564
[16] Barbara NP, Wrana JL, Letarte M . Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily[J]. J Biol Chem, 1999,274(2):584-594.
doi: 10.1074/jbc.274.2.584
[17] Kapur NK, Wilson S, Yunis AA , et al. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure[J]. Circulation, 2012,125(22):2728-2738.
doi: 10.1161/CIRCULATIONAHA.111.080002
[18] Venkatesha S, Toporsian M, Lam C , et al. Soluble endoglin contributes to the pathogenesis of preeclampsia[J]. Nat Med, 2006,12(6):642-649.
doi: 10.1038/nm1429 pmid: 16751767
[19] Chatterjee A, Black SM, Catravas JD . Endothelial nitric oxide (NO) and its pathophysiologic regulation[J]. Vascul Pharmacol, 2008,49(4/5/6):134-140.
doi: 10.1016/j.vph.2008.06.008 pmid: 2592563
[20] Palmer RM, Ferrige AG, Moncada S . Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor[J]. Nature, 1987,327(6122):524-526.
doi: 10.1038/327524a0
[21] de Caterina R, Libby P, Peng HB , et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines[J]. J Clin Invest, 1995,96(1):60-68.
doi: 10.1172/JCI118074
[22] Radomski MW, Palmer RM, Moncada S . Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium[J]. Lancet, 1987,2(8567):1057-1058.
doi: 10.1016/S0140-6736(87)91481-4 pmid: 2889967
[23] Lauer T, Preik M, Rassaf T , et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action[J]. Proc Natl Acad Sci USA, 2001,98(22):12814-12819.
doi: 10.1073/pnas.221381098 pmid: 11606734
[24] Robak E, Kierstan M, Cebula B , et al. Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus[J]. Lupus, 2009,18(4):332-341.
doi: 10.1177/0961203308097572 pmid: 19276301
[25] Cervera R, Serrano R, Pons-Estel GJ , et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients[J]. Ann Rheum Dis, 2015,74(6):1011-1018.
doi: 10.1136/annrheumdis-2013-204838 pmid: 24464962
[26] Derksen RH, de Groot PG . The obstetric antiphospholipid syndrome[J]. J Reprod Immunol, 2008,77(1):41-50.
doi: 10.1016/j.jri.2006.12.003
[27] Holers VM, Girardi G, Mo L , et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss[J]. J Exp Med, 2002,195(2):211-220.
doi: 10.1084/jem.200116116 pmid: 11805148
[28] Soh MC, Pasupathy D, Gray G , et al. Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes[J]. Rheumatology(Oxford), 2013,52(9):1642-1647.
doi: 10.1093/rheumatology/ket173 pmid: 3741478
[29] Levine RJ, Lam C, Qian C , et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia[J]. N Eng J Med, 2006,355(10):992-1005.
doi: 10.1056/NEJMoa055352 pmid: 15805796
[1] Yu-hua WANG,Guo-hua ZHANG,Ling-ling ZHANG,Jun-li LUO,Lan GAO. Adrenal hemorrhage in a patient with systemic lupus erythematosus [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1178-1181.
[2] Jie-yu GU,Cui LU,Hui SHI,Cheng-de YANG. Case series and clinical analysis of 14 cases of catastrophic antiphospholipid syndrome [J]. Journal of Peking University(Health Sciences), 2018, 50(6): 1033-1038.
[3] ZHENG Xiao-Juan, DENG Xiao-Li, LIU Xiang-Yuan. Pregnancy outcome in 54 patients with antiphospholipid syndrome：a retrospective clinical study [J]. Journal of Peking University(Health Sciences), 2014, 46(2): 323-328.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd